INS and Hyperglycemia: Despite an ∼ 2-fold increase in active GLP1, olanzapine-induced hyperglycemia (Figure 2D), and reductions in serum insulin (Figure 2E) were unchanged by sitagliptin, while glucagon was elevated in animals that received both drugs (Figure 2F).